DealBook: Strict Cost-Cutters Who Want to Spend $45 Billion on a Takeover

Valeant's chief, J. Michael Pearson, has slimmed down the company, but been an aggressive acquirer, spending more than $19 billion on companies. Valeant now has Allergan, maker of Botox, in its sights.